ArticleGeroScience2026
Amyloid neuropathy, tauopathy, decreased cholinergic and dopaminergic neurons, long-term memory and motor deficits, and sleep disturbance in motopsin deficient mice.
Article in GeroScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Truncating mutation in motopsin (neurotrypsin/PRSS12) gene causes an autosomal recessive non-syndromic intellectual disability. Since motopsin cleaves agrin, motopsin deficiency causes accumulation of long form agrin. Agrin binds amyloid β (Aβ) and accelerates Aβ fibril formation in Alzheimer's disease (AD). Down's syndrome (DS) exhibits AD-like neuropathological changes. Agrin also contributes to Parkinson's disease (PD). Degeneration of cholinergic neurons is relevant to AD, whereas degeneration of dopaminergic neurons causes PD and PD-associated cognitive impairment and dementia. Although there is a functional relationship between agrin and amyloidosis, it has not been clear whether motopsin deficiency induces amyloid neuropathy or not. Here, motopsin knock-out (KO) mice increased hippocampal amyloid and phosphorylated tau deposits. Agrin and amyloid oligomers were colocalized in the amyloid angiopathy. Motopsin KO mice also exhibited motor deficits. Motopsin KO male mice decreased cholinergic neurons in the vertical limb of the diagonal band of Broca and dopaminergic neurons in the substantia nigra compacta and the ventral tegmental area, and showed long-term memory deficits for object recognition, hypoactivity, and shorter sleeping time. Motopsin KO female mice decreased cholinergic neurons in the medial septum and showed hyperactivity. The results suggest that this intellectual disability is produced by a complex mechanism relating to AD, DS, PD, PD-associated cognitive impairment, and cerebrovascular dementia. The results also suggest that motopsin KO mouse can be a novel animal model for these diseases. Development of therapeutics, that reduce amyloid and phosphorylated tau deposits and protect cholinergic and dopaminergic neurons, will be useful to prevent the progress of this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.